MSB 4.66% $1.46 mesoblast limited

Ann: LVAD Results Webcast Presentation, page-4

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 15,743 Posts.
    lightbulb Created with Sketch. 5765
    Yes and the FDA set a target re: GI Bleeding and this was achieved so hence BLA meeting being organised .... I cant see the FDA pursuing something they believe to have failed ?

    I also don’t see that the NIH would throw more $ at an additional trial if they think it was a complete waste of time / failure ?

    The pump thrombosis problem with the LVAD device made assessment of weaning difficult and I would anticipate that is why they are keen to undertake a new trial with the newer model LVAD this time around ... costs for these trials are enormous so again I cannot see NIH going to such expense if they weren’t of the opinion that it was worthwhile ?

    GLTAH
    Last edited by col69: 13/11/18
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.46
Change
0.065(4.66%)
Mkt cap ! $1.667B
Open High Low Value Volume
$1.41 $1.50 $1.40 $5.699M 3.943M

Buyers (Bids)

No. Vol. Price($)
5 122380 $1.46
 

Sellers (Offers)

Price($) Vol. No.
$1.46 11015 2
View Market Depth
Last trade - 16.10pm 11/11/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.